rs104886003
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
|
21430269 |
2011 |
rs121913273
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
|
21430269 |
2011 |
rs121913279
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
|
21430269 |
2011 |
rs121913279
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
|
21430269 |
2011 |
rs104886003
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs104886003
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs121913273
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs121913279
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs121913279
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs121913273
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |